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  Based upon the knowledges of animal experiments， some of the basic problems were discussed
on the application ofimmunotherapy in human cancers，
  It was stressed， from our animal experiments， that the irnmunological eradication of residual
tumor cells was rather strictiy limitted in the imniune host， and the adequate cytoreduction by anti－
cancer agents was essential for the establishment of successfu1 immunotherapy．
  Since the analysis of specific antigens in individual human cancers is still diMcult at present situa－
tien， it was rational to use cryoreserved autologous cancer cells as specific antigen for immunotherapy．
  The clinical use of immunopotentiators should be reevaluated carefUIIy for dose and route of
administeration， and it was proven that immunopotentiators might enhance the tumor death in
experimenta’P mice， de pending on the minute differences of their doses．
  Among numerous trials of immunotherapy in man， the success佃resu重ts had becn obtained so
far only in patients with miniinal tumor load such as stage 1， and II，
  The newer approach of immunetherapy along wTith intensive chemotherapy is to be evaluated
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Rational basis for lmmunotheropy in cancer．
        CMie Univ． T，Tzawa ＆ M・Sakurai）
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